Guidelines for reporting of statistics for clinical research in urology

Assel, Melissa; Sjoberg, Daniel D.; Elders, Andrew; Wang, Xuemei; Huo, Dezheng; Botchway, Albert; Delfino, Kristin; Fan, Yunshan; Zhao, Zhiguo; Koyama, Tatsuki; Hollenbeck, Brent K.; Qin, Rui; Zahnd, Whitney E.; Zabor, Emily C.; Kattan, Michael W.; Vickers, Andrew

doi:10.1111/bju.14640

Cited by 64 publications

(64 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All data were expressed as means ± SD, and statistical methods refer to "Guidelines for reporting of statistics for clinical research in urology" provided by Assel et al [17].The difference in the uptake of 131 I-PD-L1-Mab was assessed using ANOVA with Student-Newman-Keuls method multiple comparison test. The receiver operating characteristic (ROC) curves were drawn to evaluate the diagnostic efficacy of tumor uptake at different time points on tumors PD-L1 expression, and the areas under the curves (AUCs) at different time points were compared using the U tests.…”

Section: Discussionmentioning

confidence: 99%

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

et al. 2020

View full text Add to dashboard Cite

Background: Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors. A 131 I-labeled anti-PD-L1 monoclonal antibody tracer, 131 I-PD-L1-Mab, was developed to study the target ability of noninvasive Cerenkov luminescence imaging in colorectal cancer xenograft mice. Method: Anti-PD-L1 monoclonal antibody labeled with 131 I (131 I-PD-L1-Mab), and in vitro binding assays were used to evaluate the affinity of 131 I-PD-L1-Mab to PD-L1 and their binding level to different colorectal cancer cells, and compared with flow cytometry, Western blot analysis, and immunofluorescence staining. The clinical application value of 131 I-PD-L1-Mab was evaluated through biodistribution and Cerenkov luminescence imaging, and different tumor-bearing models expressing PD-L1 were evaluated. Results: 131 I-PD-L1-Mab showed high affinity to PD-L1, and the equilibrium dissociation constant was 1.069 × 10-9 M. The competitive inhibition assay further confirmed the specific binding ability of 131 I-PD-L1-Mab. In four different tumor-bearing models with different PD-L1 expression, the biodistribution and Cerenkov luminescence imaging showed that the RKO tumors demonstrated the highest uptake of the tracer 131 I-PD-L1-Mab, with a maximum uptake of 1.613 ± 0.738% IA/g at 48 h. Conclusions: There is a great potential for 131 I-PD-L1-Mab noninvasive Cerenkov luminescence imaging to assess the status of tumor PD-L1 expression and select patients for anti-PD-L1 targeted therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Mann-Whitney U-tests were performed for descriptive variables [32]. The Fisher's exact test was performed to compare the categorical variables.…”

Section: Discussionmentioning

confidence: 99%

Muscle Characteristics Obtained Using Computed Tomography as Prognosticators in Patients with Castration-Resistant Prostate Cancer

Lee

Park

Heo

et al. 2020

Cancers

View full text Add to dashboard Cite

Limited studies have investigated the correlation between body composition and prostate cancer outcomes. We analyzed the effect of muscle mass and quality on castration-resistant prostate cancer (CRPC) outcomes. Skeletal muscle index (SMI) and skeletal muscle attenuation (SMA) were measured for 411 patients at the L3 vertebral level using computed tomography at CRPC diagnosis and were dived to low and high groups at the value of median. Analysis of the skeletal phenotypes and age (<70 and >70 years) was performed to evaluate the effect of SMI and SMA. The median survival rates for patients with low and high SMI were 19 and 24 months (p = 0.015), and those with low and high SMAs were 15 and 26 months (p < 0.001), respectively. In the subgroup analysis by age, SMA was a significant prognosticator in both groups, while SMI was a significant prognosticator only in patients aged >70 years. Patients with low SMA + low SMI had the worst prognosis. Muscle characteristics seems to be a prognosticator in survival of CRPC patients and may be considered in treatment planning.

show abstract

“…For continuous predictors, direct comparisons of the risk ratios (odds or hazard ratios) are difficult because continuous variables are generally expressed in metrics relevant to clinical practice (eg, mg/dL or age in years). For more discussion, see section 5.6 in Assel et al 17 Lastly, it is not widely understood that the estimated associations for variables with P < .05 are biased upward in comparison with the true value in the population, whereas those with P > .05 are biased downward. 5 The upward bias is most extreme for results achieving P < .05 when statistical power is low; Button et al 18 call this phenomenon the winner's curse (see R code for an example).…”

Section: Further Considerationsmentioning

confidence: 99%

“…Adjustments for multiple testing and control of the familywise error rate or false discovery rate are critical when one is using hypothesis testing across multiple risk factors. 7,17 As mentioned earlier, when multiple predictors are of interest and the familywise error rate is not controlled through adjustments for multiple comparisons, CIs are the recommended method of analysis. For simplicity of illustration, no results presented here were adjusted for multiple comparisons.…”

Section: Further Considerationsmentioning

confidence: 99%

Assessing risk factors with information beyond P value thresholds: Statistical significance does not equal clinical importance

Putt

2020

Cancer

View full text Add to dashboard Cite

show abstract

Guidelines for reporting of statistics for clinical research in urology

Cited by 64 publications

References 5 publications

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

Muscle Characteristics Obtained Using Computed Tomography as Prognosticators in Patients with Castration-Resistant Prostate Cancer

Assessing risk factors with information beyond P value thresholds: Statistical significance does not equal clinical importance

Contact Info

Product

Resources

About